Enlivex Therapeutics Ltd. announced that the first patient has been dosed under the amended protocol for the Company?s Phase II trial evaluating Allocetra? in patients with sepsis. As previously announced, the amended protocol allows a higher SOFA score inclusion range, which allows the recruitment of patients with higher levels of sepsis severity.

Additionally, the amended protocol provides for two cohorts (treatment and placebo) rather than the prior protocol?s four-cohort structure. Allocetra? is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.

Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra?

has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.